Research Progress on Combination Therapies Based on PD-1/PD-L1 Blockade Against Malignancies and the Adjuvant Effects...

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Programmed death (PD-1) is an immune checkpoint receptor on immune cells, interacting with PD-L1 ligand found on cancer cells.
• The PD-1/PD-L1 interaction suppresses anti-tumor immune responses by inhibiting T cell functions.
• PD-1/PD-L1 inhibitors are effective anticancer agents but face limitations like low response rates and resistance.

Purpose of the Study:

• To explore the role of Traditional Chinese Medicine (TCM) as an adjuvant therapy in combination with PD-1/PD-L1 blockade for cancer treatment.
• To analyze the synergistic effects and complex mechanisms of TCM in enhancing PD-1/PD-L1 blockade efficacy.
• To identify opportunities and challenges in utilizing combined TCM and PD-1/PD-L1 blockade strategies for cancer therapy.

Main Methods:

• Review of current literature on PD-1/PD-L1 blockade in cancer therapy.
• Analysis of studies investigating the combination of PD-1/PD-L1 inhibitors with various cancer treatments, including TCM.
• Exploration of the holistic principles and mechanisms of TCM as an adjuvant therapy.

Main Results:

• Combination therapies, including with TCM, broaden cancer treatment options beyond monotherapy.
• TCM demonstrates potential synergistic effects when used alongside PD-1/PD-L1 blockade.
• The integration of TCM offers a holistic approach to potentially overcome limitations of PD-1/PD-L1 blockade.

Conclusions:

• Combining PD-1/PD-L1 blockade with TCM presents a promising avenue for improving cancer treatment efficacy.
• Further research is needed to fully elucidate the mechanisms and optimize the application of TCM in conjunction with PD-1/PD-L1 inhibitors.
• Addressing challenges and leveraging opportunities in combined therapies can advance cancer care.